November 1, 2024
Completion of Moderna’s Vaccine Production Line at Novocol Pharma Enhances Ontario’s Biomanufacturing Strength
September 17, 2024
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
September 9, 2024
Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
August 14, 2024
Moderna and Coursera Launch Free Course on mRNA Technology
July 23, 2024
David Rubenstein Joins Moderna’s Board of Directors
No current content.